Merck, known as MSD outside the United States and Canada, announced FDA’s approval of its new HIV treatment Idvynso. Idvynso is a single-tablet, two-drug regimen comprised of 100 mg doravirine and 0.25 mg islatravir. Its indication covers adults with HIV-1 infection—the most common and virulent strain of HIV—and replaces current antiretroviral regimens. FDA Parameters for Idvynso Approval Specifically, patients must previously have been virologically suppressed (HIV-1 RNA less than 50 c...